학술논문
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Document Type
article
Author
Yamile Zabana; Ignacio Marín-Jiménez; Iago Rodríguez-Lago; Isabel Vera; María Dolores Martín-Arranz; Iván Guerra; Javier P. Gisbert; Francisco Mesonero; Olga Benítez; Carlos Taxonera; Ángel Ponferrada-Díaz; Marta Piqueras; Alfredo J. Lucendo; Berta Caballol; Míriam Mañosa; Pilar Martínez-Montiel; Maia Bosca-Watts; Jordi Gordillo; Luis Bujanda; Noemí Manceñido; Teresa Martínez-Pérez; Alicia López; Cristina Rodríguez-Gutiérrez; Santiago García-López; Pablo Vega; Montserrat Rivero; Luigi Melcarne; Maria Calvo; Marisa Iborra; Manuel Barreiro de-Acosta; Beatriz Sicilia; Jesús Barrio; José Lázaro Pérez; David Busquets; Isabel Pérez-Martínez; Mercè Navarro-Llavat; Vicent Hernández; Federico Argüelles-Arias; Fernando Ramírez Esteso; Susana Meijide; Laura Ramos; Fernando Gomollón; Fernando Muñoz; Gerard Suris; Jone Ortiz de Zarate; José María Huguet; Jordina Llaó; Mariana Fe García-Sepulcre; Mónica Sierra; Miguel Durà; Sandra Estrecha; Ana Fuentes Coronel; Esther Hinojosa; Lorenzo Olivan; Eva Iglesias; Ana Gutiérrez; Pilar Varela; Núria Rull; Pau Gilabert; Alejandro Hernández-Camba; Alicia Brotons; Daniel Ginard; Eva Sesé; Daniel Carpio; Montserrat Aceituno; José Luis Cabriada; Yago González-Lama; Laura Jiménez; María Chaparro; Antonio López-San Román; Cristina Alba; Rocío Plaza-Santos; Raquel Mena; Sonsoles Tamarit-Sebastián; Elena Ricart; Margalida Calafat; Sonsoles Olivares; Pablo Navarro; Federico Bertoletti; Horacio Alonso-Galán; Ramón Pajares; Pablo Olcina; Pamela Manzano; Eugeni Domènech; Maria Esteve; on behalf of the ENEIDA registry of GETECCU
Source
Journal of Clinical Medicine, Vol 11, Iss 2, p 421 (2022)
Subject
Language
English
ISSN
2077-0383
Abstract
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.